Literature DB >> 12846690

Local infusion of the nitric oxide donor Sin-1 after angioplasty. Effects on intimal hyperplasia in porcine coronary arteries.

J Harnek1, E Zoucas, R Sjuve, A Arner, E Ekblad, H Schou, V Perez de Sá, U Stenram.   

Abstract

PURPOSE: To investigate the development of intimal hyperplasia in response to percutaneous transluminal coronary angioplasty (PTCA) followed by local delivery of the nitric oxide (NO) donor 3-morpholino-sydnonimine (SIN-1).
MATERIAL AND METHODS: Overdilation PTCA was performed in coronary arteries in 20 healthy pigs. One of the dilated segments was additionally treated with local delivery of SIN-1 for 10 min. Segments distal to the treated part of the arteries served as controls. Arteries were radiographically depicted and analyzed after 1 and 8 weeks for actin, myosin and intermediate filaments (IF), nitric oxide synthetase (NOS) and histological evaluation.
RESULTS: Segments treated with PTCA+SIN-1 showed a significantly (p=0.03) larger luminal diameter compared with PTCA only treated segments. The luminal loss after SIN-1 was not significant compared with the diameter prior to treatment. Endothelial NOS content was significantly lower in the PTCA+SIN-1 group compared with the PTCA group after 1 (p=0.03) and 8 weeks (p=0.013). IF/actin ratio after 1 week was significantly increased in PTCA-treated segments compared with untreated controls (p=0.004), and compared with PTCA+SIN-1-treated segments (p=0.004).
CONCLUSION: PTCA-induced intimal hyperplasia was potently inhibited by local delivery of the NO donor SIN-1. Momentary events at the time of injury play a significant role in the development of intimal hyperplasia and long-lasting down-regulation of the endothelial NOS expression after SIN-1 exposure is suggested. The IF/actin ratio can be useful as an early marker of intimal hyperplasia.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12846690     DOI: 10.1080/j.1600-0455.2003.00079.x

Source DB:  PubMed          Journal:  Acta Radiol        ISSN: 0284-1851            Impact factor:   1.701


  4 in total

1.  Nitric oxide delivery via a permeable balloon catheter inhibits neointimal growth after arterial injury.

Authors:  George E Havelka; Edward S Moreira; Monica P Rodriguez; Nick D Tsihlis; Zheng Wang; Janet Martínez; Joseph A Hrabie; Larry K Kiefer; Melina R Kibbe
Journal:  J Surg Res       Date:  2012-11-10       Impact factor: 2.192

2.  Nitric oxide and nanotechnology: a novel approach to inhibit neointimal hyperplasia.

Authors:  Muneera R Kapadia; Lesley W Chow; Nick D Tsihlis; Sadaf S Ahanchi; Jason W Eng; Jozef Murar; Janet Martinez; Daniel A Popowich; Qun Jiang; Joseph A Hrabie; Joseph E Saavedra; Larry K Keefer; James F Hulvat; Samuel I Stupp; Melina R Kibbe
Journal:  J Vasc Surg       Date:  2008-01       Impact factor: 4.268

3.  Heightened efficacy of nitric oxide-based therapies in type II diabetes mellitus and metabolic syndrome.

Authors:  Sadaf S Ahanchi; Vinit N Varu; Nick D Tsihlis; Janet Martinez; Charles G Pearce; Muneera R Kapadia; Qun Jiang; Joseph E Saavedra; Larry K Keefer; Joseph A Hrabie; Melina R Kibbe
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-10-17       Impact factor: 4.733

4.  Intimal hyperplasia in balloon dilated coronary arteries is reduced by local delivery of the NO donor, SIN-1 via a cGMP-dependent pathway.

Authors:  Jan Harnek; Evita Zoucas; Valéria Perez de Sá; Eva Ekblad; Anders Arner; Unne Stenram
Journal:  BMC Cardiovasc Disord       Date:  2011-06-11       Impact factor: 2.298

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.